SecBot SecBot
PRESS-RELEASE ·Filed Nov 12, 2026

ERAS

Erasca, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed4d 7h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

Monitor upcoming ERAS-4001 Phase 1 data expected in H2 2026 and ERAS-0015 data in H1 2027 for signs of efficacy; the cash runway supports multiple registration-enabling trials through 2028, reducing near-term dilution risk.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

ERAS drug pipeline →

ERAS-0015

◆ Mixed Named in this press release
Impact
Phase
Phase 1
Time to market
~3-5 years, assuming registration-enabling trials initiate in 2027 and a potential approval by ~2029-2030
Next catalyst
None dated

What to watchERAS-0015 Phase 1 data is genuinely strong (57-62% response rates in difficult-to-treat tumors) but the stock carries heavy legal baggage, a securities class action and patent-infringement allegations from Revolution Medicines. The stock recovered from its April 48% crash to ~$18; watch for the August 10, 2026 lead-plaintiff deadline and any developments in the Revolution Medicines patent dispute, which could swing shares sharply. The registration-enabling trial initiations in H1 2027 are the next major de-risking catalyst.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$15.66
T+0 close · Nov 12, 2026 · via day close
Latest settled
−3.51%
T+1 · $15.11
Vs SPY
−1.60%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $15.66entry
  2. T+1 · 17h ago −3.51%α −1.60% · $15.11
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Erasca reported a Q3 2026 net loss of $51.3M ($0.15/share), wider than the $30.6M loss a year ago, driven by increased R&D spending. The company highlighted FDA Fast Track Designation for ERAS-0015 in pancreatic cancer and a strong cash position of $948M following a $632.5M public offering, funding key milestones through 2027-2028.

Key Financial Metrics

EPS
−$0.15

Key Facts

  • Net loss of $51.3M ($0.15/share) for Q3 2026 vs $30.6M ($0.11/share) in Q3 2025
  • Cash, cash equivalents, and marketable securities of $947.8M as of Sep 30, 2026, up from $341.8M at Dec 31, 2025
  • Completed upsized public offering in July 2026 raising ~$632.5M in gross proceeds
  • FDA Fast Track Designation granted to ERAS-0015 for metastatic pancreatic adenocarcinoma in August 2026
  • R&D expenses rose to $47.2M from $22.5M YoY, driven by clinical trial and preclinical costs
  • Key upcoming milestones: Phase 1 ERAS-0015 data H1 2027, Phase 3 pancreatic trial initiation 2027, Phase 1 ERAS-4001 data H2 2026

Financial Impact

Net loss increased by $20.7M YoY; cash position strengthened by $606M from year-end 2025 due to $632.5M offering

net losscash positionR&D expenses

Risk Factors

  • Clinical-stage company with no approved products; net losses expected to continue
  • R&D expenses are rising sharply as trials advance, potentially accelerating cash burn
  • Forward-looking statements subject to clinical trial risks and regulatory uncertainties

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
81% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402156

Track record

26 reports on ERAS

Performance horizon

4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +95.35% at T+60 after the Apr 27, 2026 report. 7 of 8 went positive at some point.

Filters
  1. Nov 16, 2026today 144 Neutral 2/10 Entry $15.21 Now $15.11 −0.66% settles Feb 12
  2. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.31 Now $15.11 −1.31% settles Feb 12
  3. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $15.35 Now $15.11 −1.56% settles Feb 12
  4. Nov 12, 20264d ago Press Release Neutral 4/10 Viewing Entry $15.66 Now $15.11 −3.51% settles Feb 11
  5. Nov 2, 202614d ago Institutional Cluster Neutral 3/10 Entry $14.64 Now $15.11 +3.21% settles Feb 1
  6. Oct 16, 20264w ago 8-K Neutral 2/10 Entry $13.39 Now $15.11 +12.85% settles Jan 13
  7. Aug 24, 202612w ago 8-K Bullish 5/10 Entry $17.60 Now $15.11 −14.15% settles Nov 17
  8. Aug 17, 202613w ago 144 Neutral 3/10 Entry $18.28 to $15.61 Now $15.11 −17.34% ▼ −14.61% −11.84% vs SPY
  9. Aug 13, 202613w ago Institutional Cluster Bullish 6/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
  10. Aug 12, 202613w ago 3 Neutral 2/10 Entry $17.86 to $14.41 Now $15.11 −15.40% ▼ −19.32% −13.84% vs SPY
Showing 10 of 26

US Market Status

Market Closed · Opens in 9h 29m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 12, 2026